To discover and secure a new engine for growth, we are utilizing A&D (Acquisition & Development) and C&D (Connect & Development) strategies to advance into the new area of Biohealthcare.

Soulbrain has striven to achieve continuous growth and business diversification, and newly advanced into the cosmetics industry through the acquisition of cosmetics professional Genic Co., Ltd., in 2015. Through our manufacturing production and quality control technology accumulated over a long period, we were able to produce high quality bio materials. Genic produces cosmetics including hydrogel mask packs, and is operating manufacturing facilities domestically and in China.

In addition, we have also advanced into the digital healthcare (IT/BT) industry through investment in UBCARE Co., Ltd., which is developing a hospital electronic health record (EHR) solution, and with further strategic investment for diversification of products in 2016 in Life Semantics Co., Ltd., a developer of a personal health record (PHR) platform.

In 2018, we made a strategic investment in L&C Bio Inc., experts in regenerative medicine R&D using hybrid bio/nano (BT/NT) materials.

With a vision of finding a wide range of new growth engines for entering the Biohealthcare field, after acquisition of ARK Diagnostics, North American experts in in vitro diagnostic (IVD) reagents, for our Reagent-Platform (Device) Business, we strategically invested in the IVD Device Platform experts, Seer Inc.

In order to become a company with key capabilities in cutting-edge biomaterials, we made a strategic investment in the cell therapy researchers Bionoxx Inc. and are further diversifying our product portfolio, and we are continuously monitoring the eco-friendly materials and environmental monitoring (NT/BT/ET) fields with great interest.

We expect to be able to secure a leading position through bold investments ahead of other competitors.